Utilization of neoadjuvant chemotherapy in high‐risk, node‐negative early breast cancer

Bibliographic Details
Title: Utilization of neoadjuvant chemotherapy in high‐risk, node‐negative early breast cancer
Authors: Ipshita Prakash, N. Ben Neely, Samantha M. Thomas, Sarah Sammons, Rachel C. Blitzblau, Gayle A. DiLalla, Terry Hyslop, Carolyn S. Menendez, Jennifer K. Plichta, Laura H. Rosenberger, Oluwadamilola M. Fayanju, E. Shelley Hwang, Rachel A. Greenup
Source: Cancer Medicine, Vol 11, Iss 4, Pp 1099-1108 (2022)
Publisher Information: Wiley, 2022.
Publication Year: 2022
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: breast cancer, cancer management, clinical management, neoadjuvant chemotherapy, surgical oncology, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Abstract Background Controversy exists regarding the optimal sequence of chemotherapy among women with operable node‐negative breast cancers with high‐risk tumor biology. We evaluated national patterns of neoadjuvant chemotherapy (NACT) use among women with early‐stage HER2+, triple‐negative (TNBC), and high‐risk hormone receptor‐positive (HR+) invasive breast cancers. Methods Women ≥18 years with cT1‐2/cN0 HER2+, TNBC, or high recurrence risk score (≥31) HR+ invasive breast cancers who received chemotherapy were identified in the National Cancer Database (2010–2016). Cochran‐Armitage and logistic regression examined temporal trends and likelihood of undergoing NACT versus adjuvant chemotherapy based on patient age and molecular subtype. Results Overall, 96,622 patients met study criteria; 25% received NACT and 75% underwent surgery first, with comparable 5‐year estimates of overall survival (0.90, 95% CI 0.892–0.905 vs 0.91, 95% CI 0.907–0.913). During the study period, utilization of NACT increased from 14% to 36% and varied according to molecular subtype (year*molecular subtype p
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2045-7634
Relation: https://doaj.org/toc/2045-7634
DOI: 10.1002/cam4.4517
Access URL: https://doaj.org/article/17bacb17c23f4bb29164cca8bf68449c
Accession Number: edsdoj.17bacb17c23f4bb29164cca8bf68449c
Database: Directory of Open Access Journals
More Details
ISSN:20457634
DOI:10.1002/cam4.4517
Published in:Cancer Medicine
Language:English